發行人剛在本網站英文版面發布一項公告，相應中文版本或會／或不會在本版面發布。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 修訂2019年限制性股份單位計劃 及2021年限制性股份單位計劃 兹提述本公司日期為2024年4月22日的通函，關於（其中包括）採納經修訂的2019年限 制性股份單位計劃及經修訂的2021年限制性股份單位計劃。除本公告另有界定者外，本 公告所用專有詞彙與通函所界定者具有相同涵義。 董事會欣然宣佈，其決議對2019年限制性股份單位計劃及2021年限制性股份單位計劃作 出如下修訂： 對2019年限制性股份單位計劃的修訂 | 條款 | 修訂 | | --- | --- | | 6.3 | 對於非美國參與者的選定參與者，限制性股份本公司依據限制性股份單位 | | | 發行股份的義務可通過以下任一方式履行：(i)由本公司或受託人在市場上 | | | 回購現有股份；(ii)使用經授權但未發行的股份、 ...

Core Viewpoint - The innovation drug sector in China is experiencing significant growth due to favorable policy developments, with the introduction of new drug listings in the national medical insurance catalog and commercial insurance, providing a stable policy outlook for innovative drug companies [1][2]. Group 1: Industry Trends - The China Hong Kong Stock Connect Innovation Drug Index increased by 0.30% as of December 11, 2025, with notable gains from companies such as Zhaoyan New Drug (+4.15%) and Rongchang Bio (+2.85%) [1]. - The national medical insurance catalog for 2025 successfully added 114 new drugs, including 50 innovative drugs, achieving a historical high success rate of 88% [1]. - The introduction of dual catalogs for medical insurance and commercial insurance is expected to directly benefit innovative drug companies, indicating a positive industry outlook [1]. Group 2: Market Opportunities - The top ten weighted stocks in the China Hong Kong Stock Connect Innovation Drug Index account for 72.68% of the index, highlighting the concentration of investment in leading innovative drug companies [2]. - The Harvest Innovation Drug ETF (520970) closely tracks the index, providing investors with access to leading companies involved in drug research, development, and production [2]. - Investors without stock accounts can leverage the Hong Kong Stock Connect Innovation Drug ETF linked fund (024700) to capitalize on the growth opportunities in the innovative drug sector [2].

每经AI快讯，金斯瑞生物科技(01548.HK)午后跌幅扩大逾11%，截至发稿跌11.07%，报13.41港元，成 交额3.07亿港元。 ...

Core Viewpoint - Kingsray Biotechnology (01548) experienced a significant decline of over 11%, trading at HKD 13.41 with a transaction volume of HKD 307 million, following a drop in the stock price of its affiliate Legend Biotech by over 7% [1] Group 1: Company Performance - Legend Biotech reported a total sales revenue of USD 1.332 billion for the first three quarters, with Q3 sales reaching USD 524 million [1] - The net loss for Legend Biotech in the first three quarters was USD 266 million, with a Q3 net loss of USD 40 million, indicating a substantial reduction in losses year-on-year and quarter-on-quarter [1] - Huatai Securities previously noted that Legend Biotech's losses are narrowing and the group's strategic vision is clear, suggesting a positive outlook for Kingsray Biotechnology's various business segments to achieve orderly profit growth and turnaround [1] Group 2: Clinical Data and Market Impact - Gilead Sciences' Kite Pharma presented new clinical data for its next-generation CAR-T therapy, anito-cel, at the 2025 American Society of Hematology (ASH) annual meeting, showing a total response rate of 96% and a complete response rate of 74%, while maintaining excellent safety [1]

Core Viewpoint - Kingsoft Biotech (01548) experienced a significant decline of over 11%, trading at HKD 13.41 with a transaction volume of HKD 307 million, following a drop in the stock price of its affiliate Legend Biotech by over 7% [1] Group 1: Company Performance - Legend Biotech reported a narrowed loss, with a clear growth blueprint, achieving sales of USD 1.332 billion for the first three quarters, including USD 524 million in Q3 [1] - The net loss for Legend Biotech in the first three quarters was USD 266 million, with a Q3 net loss of USD 40 million, showing significant year-on-year and quarter-on-quarter improvement [1] Group 2: Clinical Data and Market Impact - Gilead Sciences' Kite Pharma presented new clinical data for the next-generation CAR-T therapy anito-cel at the 2025 American Society of Hematology (ASH) annual meeting, demonstrating a total response rate of 96% and a complete response rate of 74%, while maintaining excellent safety [1] - The positive clinical results for anito-cel may impact the market perception of Kingsoft Biotech and its affiliate, as they compete in the CAR-T therapy space [1]

Core Viewpoint - Kingsray Biotechnology (01548) announced that its affiliate Legend Biotech Corporation will present long-term follow-up clinical and translational research data from the CARTITUDE-1 and CARTITUDE-4 studies on CARVYKTI (cilta-cel) for patients with relapsed or refractory multiple myeloma (RRMM) at the American Society of Hematology (ASH) annual meeting on December 6, 2025 [1] Group 1 - Legend Biotech will showcase the latest results from the Phase III study CARTITUDE-4, along with six posters demonstrating the durability of response data for CARVYKTI across different subgroups and real-world study results [1] - The presentation will also include initial human trial data for the dual-target allogeneic CAR-T candidate product LUCAR-G39D [1]

Core Viewpoint - Legend Biotech announced the presentation of long-term follow-up clinical and translational research data for CARVYKTI (cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM) at the American Society of Hematology (ASH) annual meeting on December 6, 2025 [1] Group 1: Clinical Research Findings - The CARTITUDE-1 and CARTITUDE-4 studies provided significant data on the efficacy of CARVYKTI in RRMM patients [1] - The latest results from the Phase III study CARTITUDE-4 were also presented, highlighting the ongoing research into the treatment's effectiveness [1] - Six posters were showcased, demonstrating the durability of response data for CARVYKTI across different subgroups and real-world studies [1] Group 2: New Product Development - Legend Biotech presented initial human trial data for the dual-target allogeneic CAR-T candidate product LUCAR-G39D at the ASH annual meeting [1]

Core Viewpoint - Kingsray Biotechnology (01548.HK) announced that its associate company, Legend Biotech, presented significant clinical data at the 2025 American Society of Hematology (ASH) annual meeting, highlighting the long-term follow-up results of CARVYKTI in patients with relapsed or refractory multiple myeloma (RRMM) [1] Group 1 - Legend Biotech released a press statement on December 6, 2025, detailing the CARTITUDE-1 and CARTITUDE-4 studies, which focus on CARVYKTI's efficacy in RRMM patients [1] - The presentation included the latest results from the Phase III CARTITUDE-4 study, showcasing the durability of response data across different subgroups and real-world studies [1] - Additionally, Legend Biotech introduced initial human trial data for its dual-target allogeneic CAR-T candidate product, LUCAR-G39D, during the ASH meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 自願性公告 傳奇宣佈於2025年ASH年會上公佈報告 本自願性公告由金斯瑞生物科技股份有限公司（「本公司」）作出。 本公司董事會（「董事會」）欣然宣佈，傳奇生物科技股份有限公司（「傳奇」，為本公司聯 營公司，其股份以美國存託股份形式於美國納斯達克全球精選市場上市）於2025年12月6日（紐 約時間）發佈新聞稿宣佈於2025年美國血液學會（「美國血液學會」）年會上通過一項口頭報 告公佈了CARVYKTI®（西達基奧侖賽，cilta-cel）在復發或難治性多發性骨髓瘤（RRMM）患 者中開展的CARTITUDE-1和CARTITUDE-4研究長期隨訪的臨床及轉化研究數據，以及III期研 究CARTITUDE-4的最新結果，還通過六項壁報展示了CARVYKTI®在不同亞組中的緩解持久性 數據及 ...